<SEC-DOCUMENT>0001193125-23-194057.txt : 20230726
<SEC-HEADER>0001193125-23-194057.hdr.sgml : 20230726
<ACCEPTANCE-DATETIME>20230726074231
ACCESSION NUMBER:		0001193125-23-194057
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230726
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230726
DATE AS OF CHANGE:		20230726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inozyme Pharma, Inc.
		CENTRAL INDEX KEY:			0001693011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475129768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39397
		FILM NUMBER:		231110057

	BUSINESS ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-330-4340

	MAIL ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Inozyme Pharma, LLC
		DATE OF NAME CHANGE:	20161222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d480656d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:inzy="http://www.inozyme.com/20230726" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-07-26_to_2023-07-26">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-07-26_to_2023-07-26">0001693011</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="inzy-20230726.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-07-26_to_2023-07-26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-26</xbrli:startDate> <xbrli:endDate>2023-07-26</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-07-26_to_2023-07-26">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt:datemonthdayyearen">July 26, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-07-26_to_2023-07-26">INOZYME PHARMA, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-07-26_to_2023-07-26">001-39397</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-07-26_to_2023-07-26">38-4024528</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-07-26_to_2023-07-26">321 Summer Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-07-26_to_2023-07-26">Suite 400</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-07-26_to_2023-07-26">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-07-26_to_2023-07-26">02210</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-07-26_to_2023-07-26">(857)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-07-26_to_2023-07-26">330-4340</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-07-26_to_2023-07-26">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-07-26_to_2023-07-26">INZY</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-07-26_to_2023-07-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;2.02. Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;26, 2023, Inozyme Pharma, Inc. (the &#8220;Company&#8221;) disclosed in a press release that it expects to report cash, cash equivalents, and short-term investments of approximately $140.2&#160;million as of June&#160;30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated cash, cash equivalents, and short-term investments amount as of June&#160;30, 2023 includes: (1) $16.1&#160;million in net proceeds received by the Company during the three months ended June&#160;30, 2023 for the issuance and sale of an aggregate of 2,591,995 shares of the Company&#8217;s common stock, $0.0001 par value per share (the &#8220;Common Stock&#8221;), pursuant to the Company&#8217;s Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM </sup>(the &#8220;Sales Agreement&#8221;), with Jefferies, LLC (&#8220;Jefferies&#8221;), and (2) $7.5&#160;million in principal that the Company elected to draw down in June 2023 under its Loan and Security Agreement (the &#8220;Loan Agreement&#8221;), dated July&#160;25, 2022, with K2 HealthVentures LLC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements for the Company for the three and six months ended June&#160;30, 2023 are not yet available. The estimated cash, cash equivalents, and short-term investments amount as of June&#160;30, 2023 is preliminary and unaudited, represents management&#8217;s estimate as of the date of this report, is subject to completion of the Company&#8217;s financial closing procedures for the three and six months ended June&#160;30, 2023, and does not present all necessary information for a complete understanding of the Company&#8217;s financial condition as of June&#160;30, 2023, or the Company&#8217;s results of operations for the three and six months ended June&#160;30, 2023. The actual financial results may differ materially from the preliminary estimated financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;7.01. Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;26, 2023, the Company issued a press release announcing a regulatory update for its global development strategy of <span style="white-space:nowrap">INZ-701</span> for the treatment of ENPP1 Deficiency following recent meetings with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and the Paediatric Committee (the &#8220;PDCO&#8221;) of the European Medicines Agency (the &#8220;EMA&#8221;). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Updates; Cash Runway </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, the Company is party to a Loan Agreement with K2 HealthVentures LLC. The Loan Agreement provides for up to $70.0&#160;million aggregate principal amount in term loans, subject to certain customary conditions. In June 2023, the Company elected to draw down $7.5&#160;million in principal under the Loan Agreement. Immediately following this drawdown, $37.5&#160;million of borrowing capacity remained available under the Loan Agreement, subject to the terms and conditions set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended June&#160;30, 2023, the Company issued and sold an aggregate of 2,591,995 shares of Common Stock pursuant to its Sales Agreement with Jefferies for aggregate net proceeds of $16.1&#160;million. From July&#160;1, 2023 through the date of this report, the Company issued and sold an aggregate of 962,000 additional shares of Common Stock pursuant to its Sales Agreement with Jefferies, for aggregate net proceeds of $5.1&#160;million. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects that its cash, cash equivalents, and short-term investments as of June&#160;30, 2023, will enable the Company to fund its cash flow requirements into the first quarter of 2025. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Global Development Strategy of <span style="white-space:nowrap">INZ-701</span> for the Treatment of ENPP1 Deficiency </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;26, 2023, the Company announced a regulatory update for its global development strategy of <span style="white-space:nowrap">INZ-701</span> for the treatment of ENPP1 Deficiency following recent meetings with the FDA and the PDCO of the EMA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ENERGY-3</span> Trial Design &#8211; Planned Pivotal Trial in Pediatric Patients with ENPP1 Deficiency </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to initiate the <span style="white-space:nowrap">ENERGY-3</span> pivotal trial (the <span style="white-space:nowrap">&#8220;ENERGY-3</span> trial&#8221;), a multicenter, randomized, open label trial in pediatric patients with ENPP1 Deficiency in October 2023. The <span style="white-space:nowrap">ENERGY-3</span> trial is expected to enroll up to 33 patients between the ages of one and less than 13 years across multiple sites globally and is designed primarily to assess the efficacy and safety of <span style="white-space:nowrap">INZ-701</span> in pediatric patients with ENPP1 Deficiency. Enrollment criteria for the trial include a confirmed genetic diagnosis of ENPP1 Deficiency, radiographic evidence of skeletal abnormalities and low plasma pyrophosphate (&#8220;PPi&#8221;). Patients will be randomized in a 2:1 ratio to an <span style="white-space:nowrap">INZ-701</span> arm or a control arm (conventional therapy, which is oral phosphate and active vitamin D) for 52 weeks, followed by an open label extension period during which all patients may receive <span style="white-space:nowrap">INZ-701.</span> <span style="white-space:nowrap">INZ-701</span> will be administered at a 2.4 mg/kg once weekly dose via subcutaneous injection. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ENERGY-3</span> is a single, multicenter, clinical trial with differences in the statistical treatment of endpoints, based on guidance from the FDA and PDCO, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">United States</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">European Union</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Primary Endpoint</span> &#8211; Change in plasma PPi from baseline</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Co-Primary</span> Endpoints &#8211; </span>Change in plasma PPi from baseline and Radiographic Global Impression of Change <span style="white-space:nowrap">(&#8220;RGI-C&#8221;)</span> score (p&lt;0.2)</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Secondary Endpoints</span> - <span style="white-space:nowrap">RGI-C</span> score, Rickets Severity Score (&#8220;RSS&#8221;), Growth <span style="white-space:nowrap">Z-score</span> and pharmacokinetics (&#8220;PK&#8221;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Secondary Endpoints &#8211; </span>RSS, Growth <span style="white-space:nowrap">Z-score</span> and PK</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on recommendations from the FDA, the primary endpoint of plasma PPi should be supported by consistent trends in appropriate secondary endpoints. Based on the agreed Paediatric Investigational Plan (&#8220;PIP&#8221;) with PDCO, plasma PPi and <span style="white-space:nowrap">RGI-C</span> are <span style="white-space:nowrap">co-primary</span> endpoints, with a relaxed <span style="white-space:nowrap">p-value</span> of &lt;0.2 for <span style="white-space:nowrap">RGI-C.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Planned Pivotal Trials in Infants and Adolescent/Adult Patients with ENPP1 Deficiency </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to conduct the <span style="white-space:nowrap">ENERGY-2</span> pivotal trial (the <span style="white-space:nowrap">&#8220;ENERGY-2</span> trial&#8221;), an open label, single arm trial in infants with ENPP1 Deficiency, based on the PIP agreed upon by PDCO. The trial is expected to be initiated outside of the United States. The trial&#8217;s <span style="white-space:nowrap">co-primary</span> endpoints will be change in plasma PPi from baseline and survival. The trial is expected to enroll up to 12 infants between birth and up to 12 months of age. Primary endpoint data from this trial will be compared to a natural history control group with patients matched on covariates associated with mortality. Discussions are ongoing with the FDA regarding the design of a potential pivotal trial of <span style="white-space:nowrap">INZ-701</span> in infants with ENPP1 Deficiency in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending regulatory discussions and appropriate financial resources, the Company also plans to conduct the <span style="white-space:nowrap">ENERGY-4</span> pivotal trial (the <span style="white-space:nowrap">&#8220;ENERGY-4</span> trial&#8221;), a multicenter, randomized, controlled trial in adolescents and adults with ENPP1 Deficiency. In the United States, the trial&#8217;s sole primary endpoint is expected to be change in plasma PPi from baseline, supported by trends in appropriate secondary endpoints, and in the European Union, the trial&#8217;s <span style="white-space:nowrap">co-primary</span> endpoints are expected to be change in plasma PPi from baseline and bone mineral content/density. Subject to regulatory review, the trial is expected to enroll up to 30 patients 13 years and older, and patients will be randomized in a 2:1 ratio to an <span style="white-space:nowrap">INZ-701</span> arm or a control arm (conventional therapy, which is oral phosphate and active vitamin D). </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Basis for Planned Marketing Applications </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on regulatory feedback from the FDA and EMA, positive data from the ongoing and planned clinical trials of <span style="white-space:nowrap">INZ-701</span> in patients with ENPP1 Deficiency, including comprehensive data demonstrating clinical impact of plasma PPi, could provide the basis for the Company&#8217;s submission of marketing applications in both the United States and the European Union. These data will include final results from the Company&#8217;s ongoing Phase 1/2 trial in adults with ENPP1 Deficiency, available results from the Company&#8217;s ongoing <span style="white-space:nowrap">ENERGY-1</span> trial (the <span style="white-space:nowrap">&#8220;ENERGY-1</span> trial&#8221;), a Phase 1b clinical trial of <span style="white-space:nowrap">INZ-701</span> in infants with ENPP1 Deficiency, available results from the planned pivotal <span style="white-space:nowrap">ENERGY-2</span> trial in infants to be initiated outside of the United States, and final results from the planned pivotal <span style="white-space:nowrap">ENERGY-3</span> trial in pediatric patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If these marketing applications are approved, the Company expects to commercially launch <span style="white-space:nowrap">INZ-701</span> for infants and pediatric patients as early as the second half of 2026. Data from the planned <span style="white-space:nowrap">ENERGY-4</span> trial in adolescent and adult patients with ENPP1 Deficiency may provide a basis for a supplemental marketing application. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anticipated Milestones for ENPP1 Deficiency Program </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to report interim data from the first three cohorts of the ongoing Phase 2 portion of the Phase 1/2 clinical trial of <span style="white-space:nowrap">INZ-701</span> in adults with ENPP1 Deficiency in September 2023. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company anticipates initiating the <span style="white-space:nowrap">ENERGY-3</span> trial, a pivotal trial of <span style="white-space:nowrap">INZ-701</span> in pediatric patients with ENPP1 Deficiency in October 2023. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to report topline data from the first three cohorts of the ongoing Phase 2 portion of the ongoing Phase 1/2 clinical trial of <span style="white-space:nowrap">INZ-701</span> in adults with ENPP1 Deficiency in the first quarter of 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company anticipates initiating the <span style="white-space:nowrap">ENERGY-2</span> trial, a pivotal trial of <span style="white-space:nowrap">INZ-701</span> in infants with ENPP1 Deficiency, outside of the United States in the second quarter of 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to report interim data from the ongoing <span style="white-space:nowrap">ENERGY-1</span> trial, a Phase 1b clinical trial of <span style="white-space:nowrap">INZ-701</span> in infants with ENPP1 Deficiency in the second half of 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company anticipates reporting topline data from the <span style="white-space:nowrap">ENERGY-3</span> trial in <span style="white-space:nowrap">mid-2025.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Trial of <span style="white-space:nowrap">INZ-701</span> in Patients with ABCC6 Deficiency </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently conducting a Phase 1/2 clinical trial of <span style="white-space:nowrap">INZ-701</span> in adults with ABCC6 Deficiency at sites in the United States and Europe. The trial is designed to primarily assess the safety and tolerability of <span style="white-space:nowrap">INZ-701</span> in adults with ABCC6 Deficiency, as well as characterize the pharmacokinetic and pharmacodynamic profile of <span style="white-space:nowrap">INZ-701,</span> including the evaluation of levels of plasma PPi and other biomarkers. The Company plans to report interim data from the ongoing Phase 2 portion of this trial in September 2023 and topline data from the ongoing Phase 2 portion of this trial in the first quarter of 2024. Subject to regulatory review and sufficient funding, the Company plans to initiate a Phase 2 clinical trial of <span style="white-space:nowrap">INZ-701</span> in adults with ABCC6 Deficiency in the fourth quarter of 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibit is furnished herewith: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d480656dex991.htm">Press Release dated July&#160;26, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this Current Report on Form <span style="white-space:nowrap">8-K</span> about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the timing and design of the Company&#8217;s ongoing and planned clinical trials, the potential benefits of <span style="white-space:nowrap">INZ-701,</span> and the timing and contents of the Company&#8217;s planned global development strategy, the availability and timing of clinical trial data, planned regulatory filings and the basis for such filings, the timing of the planned commercial launch of <span style="white-space:nowrap">INZ-701,</span> if approved, and the period over which the Company believes that its existing cash, cash equivalents, and short term investments will be sufficient to fund its cash flow requirements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company&#8217;s ability to conduct its ongoing clinical trials of <span style="white-space:nowrap">INZ-701</span> for ENPP1 Deficiency and ABCC6 Deficiency; enroll patients in ongoing and planned trials; obtain and maintain necessary approvals from the FDA, EMA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; obtain clinically meaningful results with respect to novel endpoints; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; comply with the covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#8217;s actual results to differ from those contained in the forward-looking statements, see the &#8220;Risk Factors&#8221; section in the Company&#8217;s most recent Annual Report on Form <span style="white-space:nowrap">10-K</span> filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors, in the Company&#8217;s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form <span style="white-space:nowrap">8-K</span> represent the Company&#8217;s views as of the date hereof and should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#8217;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">INOZYME PHARMA, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: July&#160;26, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Douglas A. Treco</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: Douglas A. Treco <br />Title: Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d480656dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inozyme Pharma Announces Updates on Global Development Strategy of <FONT STYLE="white-space:nowrap">INZ-701</FONT> for the Treatment of
ENPP1 Deficiency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and
<FONT STYLE="white-space:nowrap">co-primary</FONT> endpoint in the EU for planned <FONT STYLE="white-space:nowrap">ENERGY-3</FONT> pivotal trial in pediatric patients - </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- <FONT STYLE="white-space:nowrap">ENERGY-3</FONT> pivotal trial in pediatric patients expected to initiate in October 2023, topline data
expected to be reported in <FONT STYLE="white-space:nowrap">mid-2025</FONT> - </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Updated cash runway expected to fund cash flow requirements
into Q1 2025 - </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Company to host conference call today at 8am ET - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON, July</B><B></B><B>&nbsp;26, 2023</B> &#151;<B>&nbsp;<U>Inozyme Pharma, Inc</U>.</B>&nbsp;(Nasdaq: INZY) (&#147;Inozyme&#148; or the
&#147;Company&#148;), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced a regulatory update for its global development
strategy of <FONT STYLE="white-space:nowrap">INZ-701</FONT> for the treatment of ENPP1 Deficiency following recent meetings with the United States (U.S.) Food and Drug Administration (FDA) and the Paediatric Committee (PDCO) of the European
Medicines Agency (EMA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to have finalized our pediatric pivotal trial design with PPi, a well-established natural inhibitor of
mineralization, as a primary endpoint in the U.S. and a <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoint in the EU. We have already observed that <FONT STYLE="white-space:nowrap">INZ-701</FONT> meaningfully increased PPi levels in our
ongoing trial of <FONT STYLE="white-space:nowrap">INZ-701</FONT> in adults with ENPP1 Deficiency and, based on our discussions with regulators in the U.S. and EU, we believe we have a clear path forward in our clinical development program for the
treatment of ENPP1 Deficiency,&#148; said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ENERGY-3</FONT> Trial
Design &#150; Planned Pivotal Trial in Pediatric Patients with ENPP1 Deficiency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to initiate the
<FONT STYLE="white-space:nowrap">ENERGY-3</FONT> pivotal trial, a multicenter, randomized, open label trial in pediatric patients with ENPP1 Deficiency in October 2023. The <FONT STYLE="white-space:nowrap">ENERGY-3</FONT> trial is expected to enroll
up to 33 patients between the ages of one and less than 13 years across multiple sites globally and is designed primarily to assess the efficacy and safety of <FONT STYLE="white-space:nowrap">INZ-701</FONT> in pediatric patients with ENPP1
Deficiency. Enrollment criteria for the trial include a confirmed genetic diagnosis of ENPP1 Deficiency, radiographic evidence of skeletal abnormalities and low plasma PPi. Patients will be randomized in a 2:1 ratio to an <FONT
STYLE="white-space:nowrap">INZ-701</FONT> arm or a control arm (conventional therapy, i.e., oral phosphate and active vitamin D) for 52 weeks, followed by an open label extension period during which all patients may receive <FONT
STYLE="white-space:nowrap">INZ-701.</FONT> <FONT STYLE="white-space:nowrap">INZ-701</FONT> will be administered at a 2.4 mg/kg once weekly dose via subcutaneous (SC) injection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ENERGY-3</FONT> is a single, multicenter, clinical trial with differences in the statistical treatment of endpoints, based on
guidance from the FDA and PDCO, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EU</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Primary Endpoint</B> &#150; Change in plasma PPi from baseline</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Co-Primary</FONT> Endpoints &#150; </B>Change in plasma PPi from baseline and Radiographic Global Impression of Change <FONT STYLE="white-space:nowrap">(RGI-C)</FONT> score (p&lt;0.2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Secondary Endpoints</B> &#150; <FONT STYLE="white-space:nowrap">RGI-C</FONT> score, Rickets Severity Score (RSS), Growth <FONT STYLE="white-space:nowrap">Z-score</FONT> and pharmacokinetics (PK)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Secondary Endpoints &#150; </B>RSS, Growth <FONT STYLE="white-space:nowrap">Z-score</FONT> and PK</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on recommendations from the FDA, the primary endpoint of plasma PPi should be supported by consistent
trends in appropriate secondary endpoints. Based on the agreed Paediatric Investigational Plan (PIP) with PDCO, plasma PPi and <FONT STYLE="white-space:nowrap">RGI-C</FONT> are <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoints, with a
relaxed <FONT STYLE="white-space:nowrap">p-value</FONT> of &lt;0.2 for <FONT STYLE="white-space:nowrap">RGI-C.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Planned Pivotal Trials in
Infants and Adolescent/Adult Patients with ENPP1 Deficiency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to conduct the <FONT STYLE="white-space:nowrap">ENERGY-2</FONT> pivotal
trial, an open label, single arm trial in infants with ENPP1 Deficiency, based on the Paediatric Investigational Plan (PIP) agreed upon by PDCO. The trial is expected to be initiated outside of the U.S. The trial&#146;s <FONT
STYLE="white-space:nowrap">co-primary</FONT> endpoints will be change in plasma PPi from baseline and survival. The trial is expected to enroll up to 12 infants between birth and up to 12 months of age. Primary endpoint data from this trial will be
compared to a natural history control group with patients matched on covariates associated with mortality. Discussions are ongoing with the FDA regarding the design of a potential pivotal trial of <FONT STYLE="white-space:nowrap">INZ-701</FONT> in
infants with ENPP1 Deficiency in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending regulatory discussions and appropriate financial resources, the Company also plans to conduct the <FONT
STYLE="white-space:nowrap">ENERGY-4</FONT> pivotal trial, multicenter, randomized, controlled trial in adolescents and adults with ENPP1 Deficiency. In the U.S., the trial&#146;s sole primary endpoint is expected to be change in plasma PPi from
baseline, supported by trends in appropriate secondary endpoints, and in the EU, the trial&#146;s <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoints are expected to be change in plasma PPi from baseline and bone mineral content/density.
Subject to regulatory review, the trial is expected to enroll up to 30 patients 13 years and older, and patients will be randomized in a 2:1 ratio to an <FONT STYLE="white-space:nowrap">INZ-701</FONT> arm or a control arm (conventional therapy,
i.e., oral phosphate and active vitamin D). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Planned Marketing Applications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on regulatory feedback from the FDA and EMA, positive data from the ongoing and planned clinical trials of
<FONT STYLE="white-space:nowrap">INZ-701</FONT> in patients with ENPP1 Deficiency, including comprehensive data demonstrating clinical impact of plasma PPi, could provide the basis for the Company&#146;s submission of marketing applications in both
the U.S. and EU. These data will include final results from the Company&#146;s ongoing Phase 1/2 trial in adult patients with ENPP1 Deficiency, available results from the Company&#146;s ongoing <FONT STYLE="white-space:nowrap">ENERGY-1</FONT> trial,
a Phase 1b trial of <FONT STYLE="white-space:nowrap">INZ-701</FONT> in infants with ENPP1 Deficiency, available results from the planned pivotal <FONT STYLE="white-space:nowrap">ENERGY-2</FONT> trial in infants to be initiated <FONT
STYLE="white-space:nowrap">ex-U.S.,</FONT> and final results from the planned pivotal <FONT STYLE="white-space:nowrap">ENERGY-3</FONT> trial in pediatric patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If these marketing applications are approved, the Company expects to commercially launch <FONT STYLE="white-space:nowrap">INZ-701</FONT> for infant and
pediatric patients as early as the second half of 2026. Data from the planned <FONT STYLE="white-space:nowrap">ENERGY-4</FONT> trial in adolescent and adult patients with ENPP1 Deficiency may provide a basis for a supplemental marketing application.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anticipated Milestones for ENPP1 Deficiency Program </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim data from Cohorts <FONT STYLE="white-space:nowrap">1-3</FONT> in the Phase 2 portion of the ongoing Phase
1/2 trial in adults &#150; September 2023 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of <FONT STYLE="white-space:nowrap">ENERGY-3</FONT> trial, a pivotal trial in pediatric patients
&#150; October 2023 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Topline data from Cohorts <FONT STYLE="white-space:nowrap">1-3</FONT> in the Phase 2 portion of the ongoing Phase
1/2 trial in adults &#150; Q1 2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of <FONT STYLE="white-space:nowrap">ENERGY-2</FONT> trial, a pivotal trial in infants, ex U.S. &#150;
Q2 2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim data from <FONT STYLE="white-space:nowrap">ENERGY-1</FONT> trial, a Phase 1b trial in infants &#150; 2H
2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Topline data from <FONT STYLE="white-space:nowrap">ENERGY-3</FONT> trial, a pivotal trial in pediatric patients
&#150; <FONT STYLE="white-space:nowrap">Mid-2025</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Runway Guidance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to report cash, cash equivalents, and short-term investments of approximately $140.2&nbsp;million as of June&nbsp;30, 2023. The estimated
cash, cash equivalents, and short-term investments amount is preliminary and unaudited, represents management&#146;s estimate as of the date of this press release, is subject to completion of the Company&#146;s financial closing procedures for the
quarter ended June&nbsp;30, 2023 and does not present all necessary information for a complete understanding of the Company&#146;s financial condition as of June&nbsp;30, 2023, or the Company&#146;s results of operations for the quarter ended
June&nbsp;30, 2023. The actual financial results may differ materially from the preliminary estimated financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on its current plans,
the Company anticipates its cash, cash equivalents, and short-term investments as of June&nbsp;30, 2023, will enable the Company to fund cash flow requirements into the first quarter of 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inozyme will host a conference call and
webcast to discuss its global development strategy for <FONT STYLE="white-space:nowrap">INZ-701</FONT> in patients with ENPP1 Deficiency today, July&nbsp;26, 2023, at 8am ET. The live webcast will be accessible through the <U>Investor
Relations</U>&nbsp;section of Inozyme&#146;s website under <U>News&nbsp;&amp; Events</U>. To access the live call by phone, dial
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-270-2148</FONT></FONT></FONT> (domestic) or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-412-902-6510</FONT></FONT></FONT> (international) and ask to be connected to the&nbsp;Inozyme Pharma&nbsp;call.&nbsp;For those unable to participate
live, a replay will be available in the <U>Investor Relations</U>&nbsp;section of Inozyme&#146;s website for a limited time following the event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
ENPP1 Deficiency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ENPP1 Deficiency is a progressive condition that manifests as a spectrum of diseases. The estimated genetic prevalence of ENPP1
Deficiency is approximately 1 in 64,000 pregnancies worldwide. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI), which is characterized by extensive vascular
calcification and intimal proliferation (overgrowth of smooth muscle cells inside blood vessels), resulting in myocardial infarction, stroke, or cardiac or multiorgan failure. Approximately 50% of infants with ENPP1 Deficiency die within six months
of birth. Children with ENPP1 Deficiency typically develop rickets, a condition diagnosed as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adults can develop osteomalacia (softened bones). ARHR2 and osteomalacia lead to pain and
mobility issues. Patients can also exhibit signs and symptoms of hearing loss, arterial and joint calcification, and cardiovascular complications. There are no approved therapies for ENPP1 Deficiency. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INZ-701</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INZ-701,</FONT> a recombinant Fc fusion protein, is an ENPP1 enzyme replacement therapy in development for the treatment of
rare disorders of the vasculature, soft tissue, and skeleton. In preclinical studies, the experimental therapy has shown potential to prevent pathologic mineralization and intimal proliferation (the overgrowth of smooth muscle cells inside blood
vessels), which can drive morbidity and mortality in devastating genetic disorders such as ENPP1 Deficiency and ABCC6 Deficiency. <FONT STYLE="white-space:nowrap">INZ-701</FONT> is currently in clinical trials for the treatment of ENPP1 Deficiency
and ABCC6 Deficiency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inozyme Pharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inozyme
Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing
<FONT STYLE="white-space:nowrap">INZ-701,</FONT> an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases.
<FONT STYLE="white-space:nowrap">INZ-701</FONT> is currently in clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more
information, please visit<B>&nbsp;<U>www.inozyme.com</U></B>&nbsp;and follow us on<B>&nbsp;<U>LinkedIn</U></B>,<B>&nbsp;<U>Twitter</U></B>, and<B>&nbsp;<U>Facebook</U></B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical
facts, may constitute &#147;forward-looking statements&#148; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the timing and design of our clinical
trials, the potential benefits of <FONT STYLE="white-space:nowrap">INZ-701,</FONT> the timing and contents of our planned global development strategy, the availability and timing of clinical trial data, planned regulatory filings and the basis for
such filings, the timing of the planned commercial launch of <FONT STYLE="white-space:nowrap">INZ-701,</FONT> if approved, and the period over which we believe that our existing cash, cash equivalents and short term investments will be sufficient to
fund our cash flow requirements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely
from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company&#146;s ability to conduct its ongoing clinical trials of <FONT
STYLE="white-space:nowrap">INZ-701</FONT> for ENPP1 Deficiency and ABCC6 Deficiency; enroll patients in ongoing and planned trials; obtain and maintain necessary approvals from the FDA, EMA, and other regulatory authorities; continue to advance its
product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; obtain clinically meaningful results with
respect to novel endpoints; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates;
manage expenses; comply with the covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors,
any of which could cause the Company&#146;s actual results to differ from those contained in the forward-looking statements, see the &#147;Risk Factors&#148; section in the Company&#146;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission (SEC), as well as discussions of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential risks, uncertainties, and other important factors, in the Company&#146;s most recent filings with the SEC. In addition, the forward-looking statements included in this press release
represent the Company&#146;s views as of the date hereof and should not be relied upon as representing the Company&#146;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause
the Company&#146;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inozyme Pharma </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stefan Riley, Director of IR and Corporate
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(857) <FONT STYLE="white-space:nowrap">330-8871</FONT> <B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>stefan.riley@inozyme.com</B></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SmithSolve</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt Pera </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(973) <FONT STYLE="white-space:nowrap">886-9150</FONT> <B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>matt.pera@smithsolve.com</B></U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>inzy-20230726.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 7/26/2023 3:39:14 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:inzy="http://www.inozyme.com/20230726"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.inozyme.com/20230726"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inzy-20230726_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inzy-20230726_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>inzy-20230726_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 7/26/2023 3:39:14 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>inzy-20230726_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 7/26/2023 3:39:15 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inzy-20230726.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139909970332336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001693011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOZYME PHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-4024528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Summer Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-4340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INZY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d480656d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inzy-20230726.xsd" xlink:type="simple"/>
    <context id="duration_2023-07-26_to_2023-07-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-07-26_to_2023-07-26">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-07-26_to_2023-07-26"
      id="Hidden_dei_EntityCentralIndexKey">0001693011</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-07-26_to_2023-07-26">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-07-26_to_2023-07-26">2023-07-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-07-26_to_2023-07-26">INOZYME PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-07-26_to_2023-07-26">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-07-26_to_2023-07-26">001-39397</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-07-26_to_2023-07-26">38-4024528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-07-26_to_2023-07-26">321 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-07-26_to_2023-07-26">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-07-26_to_2023-07-26">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-07-26_to_2023-07-26">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-07-26_to_2023-07-26">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-07-26_to_2023-07-26">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-07-26_to_2023-07-26">330-4340</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-07-26_to_2023-07-26">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-07-26_to_2023-07-26">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-07-26_to_2023-07-26">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-07-26_to_2023-07-26">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-07-26_to_2023-07-26">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-07-26_to_2023-07-26">INZY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-07-26_to_2023-07-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-07-26_to_2023-07-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-07-26_to_2023-07-26">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 3SWZ5IE<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !//?I6>(8L[7\$  #$$0  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 3SWZ5I^@&_"Q @  X@P   T
M             ( !PPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !//?I6
MEXJ[',     3 @  "P              @ &?#P  7W)E;',O+G)E;'-02P$"
M% ,4    " !//?I6'#AEZC\!   \ @  #P              @ &($   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 3SWZ5B0>FZ*M    ^ $  !H
M         ( !]!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 3SWZ5F60>9(9 0  SP,  !,              ( !V1(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d480656d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d480656d8k.htm">d480656d8k.htm</File>
    <File>d480656dex991.htm</File>
    <File>inzy-20230726.xsd</File>
    <File>inzy-20230726_lab.xml</File>
    <File>inzy-20230726_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d480656d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d480656d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inzy-20230726_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inzy-20230726_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inzy-20230726.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "inzy",
   "nsuri": "http://www.inozyme.com/20230726",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d480656d8k.htm",
      "contextRef": "duration_2023-07-26_to_2023-07-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d480656d8k.htm",
      "contextRef": "duration_2023-07-26_to_2023-07-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com//20230726/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-23-194057-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-194057-xbrl.zip
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M#W@:6$$C/,5((\"O*"!@QD>C6,$+$:'KC%TR1%9GV;R,GQ<+]./S&-\YX'_
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M<XCATKG*9HQ=7U\GQ5PHJV7MR()-<ETRB.-._^/%=_BKL9[!%"5RBU!RZ]#
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M>,4;0Q_)AC7ZE5X0T1^IS5LQYBOV(O"+Z:\!>X,=$_1/86C(/Y=L"'A=!K@
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MXA%'HD2[J<%(RS4Z'PTYJIR26K8<ES<D6*KUU*8_F(QI'%G?X]C-:VMI4V:
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MY&]02P$"% ,4    " !//?I6>8W/B#@A  !>QP  #@              @ $
M    9#0X,#8U-F0X:RYH=&U02P$"% ,4    " !//?I64]87@$$9  #R;
M$0              @ %D(0  9#0X,#8U-F1E>#DY,2YH=&U02P$"% ,4
M" !//?I6XZC<(T$#  !)"P  $0              @ '4.@  :6YZ>2TR,#(S
M,#<R-BYX<V102P$"% ,4    " !//?I6%:@P7:H&  "D20  %0
M    @ %$/@  :6YZ>2TR,#(S,#<R-E]L86(N>&UL4$L! A0#%     @ 3SWZ
M5MX3T7C<!   _2T  !4              ( !(44  &EN>GDM,C R,S W,C9?
=<')E+GAM;%!+!08     !0 % $ !   P2@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
